Clinical Trial Update: Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease [Phase 1]

View source ↗

Summary

Phase 1 results indicate safety and tolerability of Ecopipam, a D1 dopamine receptor antagonist, in patients with Lesch-Nyhan disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lesch-nyhan Disease

Drugs mentioned

• Ecopipam (Ecopipam)

Snippet

Sponsor: Psyadon Pharma | Conditions: Lesch-Nyhan Disease | Phase 1 | Status: COMPLETED | Results posted: 2013-04-18